Jean-Marie Ledeine

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.8K citations · Full text

Medicine, Genetics, Oncology +14

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16

Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

David M. Kendall, Cindy J. Rubin, Pharis Mohideen et al. · Diabetes Care · 2006 · 115 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Eric Van Cutsem, María Luisa Limón et al. · Annals of Oncology · 2018 · 92 citations · Full text

Medicine, Immunology, Oncology +13

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman, Sara Lonardi, Francesco Leone et al. · Journal of Clinical Oncology · 2017 · 70 citations

Life Sciences, Immunology, Oncology +17